BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23738435)

  • 21. Diagnosis and treatment of presymptomatic Wilson's disease.
    Walshe JM
    Lancet; 1988 Aug; 2(8608):435-7. PubMed ID: 2900362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
    Merle U; Schaefer M; Ferenci P; Stremmel W
    Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Wilsons disease].
    Mareček Z; Brůha R
    Vnitr Lek; 2013 Jul; 59(7):578-83. PubMed ID: 23909262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
    Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
    Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilson's disease: an update, with emphasis on new approaches to treatment.
    Brewer GJ; Yuzbasiyan-Gurkan V
    Dig Dis; 1989; 7(4):178-93. PubMed ID: 2663256
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment and management of Wilson's disease.
    Shimizu N; Yamaguchi Y; Aoki T
    Pediatr Int; 1999 Aug; 41(4):419-22. PubMed ID: 10453198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Wilson's disease in paediatric age: diagnosis and treatment. Recent advances].
    Palumbo E
    Recenti Prog Med; 2008 Nov; 99(11):561-4. PubMed ID: 19209540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Wilson disease in 2003].
    Szalay F
    Orv Hetil; 2003 Dec; 144(50):2451-8. PubMed ID: 15067983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Wilson's disease with severe neurological manifestations: response to trientine plus zinc therapy].
    Serra B; Primo J; García M; Amorós I; Aragó M; Merino C
    Gastroenterol Hepatol; 2004 May; 27(5):307-10. PubMed ID: 15117609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilson's disease: overview.
    Lucena-Valera A; Ruz-Zafra P; Ampuero J
    Med Clin (Barc); 2023 Mar; 160(6):261-267. PubMed ID: 36697289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wilson's disease in pregnancy.
    Nunns D; Hawthorne B; Goulding P; Maresh M
    Eur J Obstet Gynecol Reprod Biol; 1995 Sep; 62(1):141-3. PubMed ID: 7493698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Wilson's disease: physiopathological, clinical and therapeutic considerations].
    Pérez-Aguilar F
    Gastroenterol Hepatol; 2003 Jan; 26(1):42-51. PubMed ID: 12525328
    [No Abstract]   [Full Text] [Related]  

  • 36. [Wilson's disease and its pharmacological treatment].
    Hayashi H; Suzuki R; Wakusawa S
    Yakugaku Zasshi; 2004 Nov; 124(11):711-24. PubMed ID: 15516801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
    Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
    Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [On hepatolenticular degeneration (Wilson's disease). 3. Hepatic localization of Cu64: scintigraphic and dynamic study before and after treatment with BAL and D-penicillamine].
    D'Addabbo A; Damato VD; Germinario L; Campanella G; Boccuni N
    Acta Neurol (Napoli); 1971; 26(4):436-48. PubMed ID: 5132825
    [No Abstract]   [Full Text] [Related]  

  • 39. Adherence to treatment, a challenge even in treatable metabolic rare diseases: A cross sectional study of Wilson's disease.
    Jacquelet E; Poujois A; Pheulpin MC; Demain A; Tinant N; Gastellier N; Woimant F
    J Inherit Metab Dis; 2021 Nov; 44(6):1481-1488. PubMed ID: 34480375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.
    Weiss KH; Askari FK; Czlonkowska A; Ferenci P; Bronstein JM; Bega D; Ala A; Nicholl D; Flint S; Olsson L; Plitz T; Bjartmar C; Schilsky ML
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):869-876. PubMed ID: 28988934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.